These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 32603117)

  • 1. Discovery of Novel Selective and Orally Bioavailable Phosphodiesterase-1 Inhibitors for the Efficient Treatment of Idiopathic Pulmonary Fibrosis.
    Wu Y; Tian YJ; Le ML; Zhang SR; Zhang C; Huang MX; Jiang MY; Zhang B; Luo HB
    J Med Chem; 2020 Jul; 63(14):7867-7879. PubMed ID: 32603117
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural Modifications of Nimodipine Lead to Novel PDE1 Inhibitors with Anti-pulmonary Fibrosis Effects.
    Huang MX; Tian YJ; Han C; Liu RD; Xie X; Yuan Y; Yang YY; Li Z; Chen J; Luo HB; Wu Y
    J Med Chem; 2022 Jun; 65(12):8444-8455. PubMed ID: 35666471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural optimization of Moracin M as novel selective phosphodiesterase 4 inhibitors for the treatment of idiopathic pulmonary fibrosis.
    Wang S; Yang G; Zhang K; Chen Z; Qiu M; Hou S; Zheng T; Wu Z; Ma Q; Zhang F; Gao G; Huang YY; Zhou Q; Luo HB; Wu D
    Bioorg Chem; 2024 Aug; 149():107474. PubMed ID: 38805909
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, Synthesis, and Evaluation of Dihydropyrimidine Derivatives as Selective PDE1 Inhibitors for the Treatment of Liver Fibrosis.
    Zhao ZJ; Jiang MY; Huang MX; Yang YY; Feng LL; Zhang C; Huang YY; Luo HB; Wu Y
    J Med Chem; 2024 May; 67(10):8309-8322. PubMed ID: 38669059
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mangostanin Derivatives as Novel and Orally Active Phosphodiesterase 4 Inhibitors for the Treatment of Idiopathic Pulmonary Fibrosis with Improved Safety.
    Huang YY; Deng J; Tian YJ; Liang J; Xie X; Huang Y; Zhu J; Zhu Z; Zhou Q; He X; Luo HB
    J Med Chem; 2021 Sep; 64(18):13736-13751. PubMed ID: 34520193
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MiR-541-5p regulates lung fibrosis by targeting cyclic nucleotide phosphodiesterase 1A.
    Ren L; Yang C; Dou Y; Zhan R; Sun Y; Yu Y
    Exp Lung Res; 2017; 43(6-7):249-258. PubMed ID: 28816543
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Andrographolide ameliorates bleomycin-induced pulmonary fibrosis by suppressing cell proliferation and myofibroblast differentiation of fibroblasts via the TGF-β1-mediated Smad-dependent and -independent pathways.
    Li J; Feng M; Sun R; Li Z; Hu L; Peng G; Xu X; Wang W; Cui F; Yue W; He J; Liu J
    Toxicol Lett; 2020 Mar; 321():103-113. PubMed ID: 31706003
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel Autotaxin Inhibitor for the Treatment of Idiopathic Pulmonary Fibrosis: A Clinical Candidate Discovered Using DNA-Encoded Chemistry.
    Cuozzo JW; Clark MA; Keefe AD; Kohlmann A; Mulvihill M; Ni H; Renzetti LM; Resnicow DI; Ruebsam F; Sigel EA; Thomson HA; Wang C; Xie Z; Zhang Y
    J Med Chem; 2020 Jul; 63(14):7840-7856. PubMed ID: 32584034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reversion of in vivo fibrogenesis by novel chromone scaffolds.
    Kim HS; Yoon YM; Meang MK; Park YE; Lee JY; Lee TH; Lee JE; Kim IH; Youn BS
    EBioMedicine; 2019 Jan; 39():484-496. PubMed ID: 30611717
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of indoline-based derivatives as effective ROCK2 inhibitors for the potential new treatment of idiopathic pulmonary fibrosis.
    Fu S; Wen Y; Peng B; Tang M; Shi M; Liu J; Yang Y; Si W; Guo Y; Li X; Yan T; Kang J; Pei H; Chen L
    Bioorg Chem; 2023 Aug; 137():106539. PubMed ID: 37163811
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TNF-α-induced NF-κB activation promotes myofibroblast differentiation of LR-MSCs and exacerbates bleomycin-induced pulmonary fibrosis.
    Hou J; Ma T; Cao H; Chen Y; Wang C; Chen X; Xiang Z; Han X
    J Cell Physiol; 2018 Mar; 233(3):2409-2419. PubMed ID: 28731277
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of Potent, Selective, and Orally Bioavailable Inhibitors against Phosphodiesterase-9, a Novel Target for the Treatment of Vascular Dementia.
    Wu Y; Zhou Q; Zhang T; Li Z; Chen YP; Zhang P; Yu YF; Geng H; Tian YJ; Zhang C; Wang Y; Chen JW; Chen Y; Luo HB
    J Med Chem; 2019 Apr; 62(8):4218-4224. PubMed ID: 30916555
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of novel pyrrolo[2,1-c][1,4]benzodiazepine-3,11-dione (PBD) derivatives as selective HDAC6 inhibitors for the efficient treatment of idiopathic pulmonary fibrosis (IPF) in vitro and in vivo.
    Li Y; Yang H; Zhao X; Zhao X; Quan J; Wang L; Ma E; Ma C
    Eur J Med Chem; 2024 Sep; 275():116608. PubMed ID: 38905805
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of Potent Phosphodiesterase-9 Inhibitors for the Treatment of Hepatic Fibrosis.
    Wu Y; Wang Q; Jiang MY; Huang YY; Zhu Z; Han C; Tian YJ; Zhang B; Luo HB
    J Med Chem; 2021 Jul; 64(13):9537-9549. PubMed ID: 34142552
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis and biological evaluation of novel pyrazolopyrimidone derivatives as potent PDE1 inhibitors.
    Zhang B; Huang Y; Zhang SR; Huang MX; Zhang C; Luo HB
    Bioorg Chem; 2021 Sep; 114():105104. PubMed ID: 34186466
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Macitentan reduces progression of TGF-β1-induced pulmonary fibrosis and pulmonary hypertension.
    Bellaye PS; Yanagihara T; Granton E; Sato S; Shimbori C; Upagupta C; Imani J; Hambly N; Ask K; Gauldie J; Iglarz M; Kolb M
    Eur Respir J; 2018 Aug; 52(2):. PubMed ID: 29976656
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metformin attenuates lung fibrosis development via NOX4 suppression.
    Sato N; Takasaka N; Yoshida M; Tsubouchi K; Minagawa S; Araya J; Saito N; Fujita Y; Kurita Y; Kobayashi K; Ito S; Hara H; Kadota T; Yanagisawa H; Hashimoto M; Utsumi H; Wakui H; Kojima J; Numata T; Kaneko Y; Odaka M; Morikawa T; Nakayama K; Kohrogi H; Kuwano K
    Respir Res; 2016 Aug; 17(1):107. PubMed ID: 27576730
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis and discovery of 2(1H)-quinolone derivatives for the treatment of pulmonary fibrosis through inhibition of TGF-β/smad dependent and independent pathway.
    Xue L; Deng D; Zheng S; Tang M; Yang Z; Pei H; Chen Y; Yang T; Liu K; Ye H; Chen L
    Eur J Med Chem; 2020 Jul; 197():112259. PubMed ID: 32334267
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pirfenidone inhibits myofibroblast differentiation and lung fibrosis development during insufficient mitophagy.
    Kurita Y; Araya J; Minagawa S; Hara H; Ichikawa A; Saito N; Kadota T; Tsubouchi K; Sato N; Yoshida M; Kobayashi K; Ito S; Fujita Y; Utsumi H; Yanagisawa H; Hashimoto M; Wakui H; Yoshii Y; Ishikawa T; Numata T; Kaneko Y; Asano H; Yamashita M; Odaka M; Morikawa T; Nakayama K; Kuwano K
    Respir Res; 2017 Jun; 18(1):114. PubMed ID: 28577568
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects and mechanisms of pirfenidone, prednisone and acetylcysteine on pulmonary fibrosis in rat idiopathic pulmonary fibrosis models.
    Yu W; Guo F; Song X
    Pharm Biol; 2017 Dec; 55(1):450-455. PubMed ID: 27937011
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.